Zusammenfassung
Die Induratio penis plastica ist eine gutartige Erkrankung der Corpora cavernosa. Mikrotraumen mit nachfolgender Wundheilungsstörung unklarer Ätiologie führen durch Bildung eines unelastischen Narbengewebes im Bereich der Tunica albuginea zu den typischen Symptomen Plaquebildung, Penisschmerz, Deviation und erektile Dysfunktion. Eine kausale medikamentöse Therapie existiert nicht, obwohl vielfältige konservative Therapieoptionen einschließlich intraläsionaler Therapie diskutiert werden. Die chirurgische Korrektur der Penisverkrümmung steht häufig am Ende des Krankheitsverlaufs. Unterschiedliche Operationsverfahren werden abhängig von Deviationsgrad, Penislänge und erektiler Funktion angeboten. Diese Arbeit gibt eine Übersicht über den Krankheitsverlauf und beschreibt sowohl aktuelle konservative Therapieoptionen als auch die gängigen chirurgischen Techniken zur Deviationskorrektur.
Abstract
Peyronie’s disease is a benign disorder of the penis but the etiology is still unknown. A wound healing disorder after repetitive microtraumatic lesions with inelastic scar formation of the tunica albuginea potentially leads to the typical symptoms of penile plaque formation, penile pain, deviation and erectile dysfunction. A non-surgical therapy based on a clear pathophysiology does not exist although the benefit of several conservative treatment options is under discussion. In the stable stage of the disease patients with Peyronie’s disease frequently undergo penile surgery. Depending on the deviation angle, the penile length and the erectile dysfunction different straightening surgery can be performed. This article provides an overview of the natural history of the disease and describes present conservative management strategies and common surgical techniques for penile straightening.
Literatur
Bennet NE, Guhring P, Mulhall JP (2007) Intralesional verapamil prevents the progression of Peyronie‘s disease. J Urol 69:1181–1184
Brant WO, Dean RC, Lue TF (2006) Treatment of Peyronie‘s disease with oral pentoxifylline. Nat Clin Pract Urol 3:111–115
Cavallini G, Biagiotti G, Koverech A, Vitali G (2002) Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie‘s disease. BJU Int 89:895–900
Cipollone G, Nicolai M, Mastroprimiano G et al (1998) Betamethason versus placebo in Peyronie‘s disease. Arch Ital Urol Androl 70:165–168
Essed E, Schroeder F (1985) New surgical treatment for Peyronie‘s disease. Urology 25:582–587
Fitch WP 3rd, Easterling WJ, Talbert RL (2007) Topical verapamil HCL, topical trifluopromazine and topical magnesium sulfate for the treatment of Peyronie‘s disease – a placebo controlled pilot study. J Sex Med 4:477–484
Gonzales-Cadavid NF, Rajfer J (2010) Treatment of Peyronie‘s disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol 7(4):215–221
Greenfield JM, Shah SJ, Levine LA (2007) Verapamil verus saline in electromotive drug administration for Peyronie‘s disease: a double-blind, placebo controlled trial. J Urol 177:972–975
Hauck EW, Diemer TH, Schmelz HU, Weidner W (2006) A critical analysis of nonsurgical treatment of Peyronie‘s disease. Eur Urol 49:987–997
Hauck EW, Weidner W (2001) François de la Peyronie and the disease named after him. Lancet 357:2049–2051
Hauptmann A, Diemer T, Weidner W (2011) Reconstructive penile surgery with small-incision corporoplasty and grafting followed by a postoperative penile rehabilitation program in Peyronie‘s disease. Europ Urol Suppl 10:326 A 1055
Hellstrom WJG, Kendirci M, Matern R et al (2006) Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon-alpha2b for minimally invasive treatment for Peyronie‘s disease. J Urol 176:394–398
Jordan GH (2008) The use of intralesional clostridial collagenase injection therapy for Peyronie‘s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 5:180–187
Kadioglu A, Sanli O, Akman T et al (2007) Graft materials in Peyronie‘s disease surgery: a comprehenisve review. J Sex Med 4:581–595
Kadioglu A, Tefekli A, Köksal T et al (2000) Treatment of Peyronie‘s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 12:169–175
Lue TF, Giuliano F, Montorsi F et al (2004) Summary of recommendations on sexual dysfunctions in men. J Sex Med 1:6–23
Moreno SA, Morgentaler A (2009) Testosterone deficiency and Peyronie‘s disease: pilot data suggesting a significant relationship. J Sex Med 6:1729-1735
Mulhall JP, Creech SD, Boorjian SA et al (2004) Subjective and objective analysis of the prevalence of Peyronie‘s disease in a population of men presenting for prostate cancer screening. J Urol 171:2350–2353
Mulhall JP, Schiff J, Guhring P (2006) An analysis of the natural history of Peyronie‘s disease. J Urol 175:2115–2118
Nesbit R (1965) Congenital curvature of the phallus: report of three cases with description of corrective operation. J Urol 93:230–232
Palmieri A, Imbimbo C, Longo N et al (2009) A first prospective, randomised, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie‘s disease. Eur Urol 56:363-370
Pryor JP, Farell CR (1983) Controlled clinical trial of vitamine E in Peyronie‘s disease. Prog Reprod Biol Med 9:41–45
Ralph D, Gonzalez-Cadavid N, Mirone V et al (2010) The management of Peyronie‘s disease. Evidence-based 2010 Guidelines. J Sex Med 7:2359–2374
Ralph DJ, Brooks MD, Botazzo GF, Pryor JP (1992) The treatment of Peyronie‘s disease with tamoxifen. Br J Urol 70:648-651
Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F (2010) A double-blind, placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie‘s disease. BJU Int 106:240–248
Safarinejad MR (2004) Therapeutic effects of colchicine in the management of Peyronies‘s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 16:238–243
Safarinejad MR, Hosseini SY, Kolahi AA (2007) Comparison of vitamin E and propionyl-L-carnitine with early chronic Peyronie‘s disease: a double-blind, placebo controlled, randomized study. J Urol 178:1398–1403
Teloken C, Rhoden EL, Grazziotin TM et al (1999) Tamoxifen vs. placebo in the treatment of Peyronie‘s diesase. J Urol 162:2003–2005
Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009) Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick March 2009. http://www.cebm.net/index.aspx?o=1025
Vardi Y, Levine LA, Chen J et al (2009) Is there a place for conservative treatment in Peyronie‘s disease? J Sex Med 6:903–909
Weidner W, Hauck EW, Schnitker J (2005) Potassium paraaminobenzoate (POTABA®) in the treatment of Peyronie‘s disease: a prospective, placebo-controlled randomized study. Eur Urol 47:530–536
Wilson SK, Delk 2nd JR (1994) A new treatment of Peyronie‘s disease: modeling the penis over an inflatable penile prothesis. J Urol 152:1121–1123
Wiltink J, Hauck EW, Phädoyanon M et al (2003) Validation of the German version of the IIEF in patients with erectile dysfunction, Peyronie‘s disease and controls. Int J Imp Res 15:192–197
Zargooshi J (2004) Trauma as a cause of Peyronie‘s disease: penile fracture as a model of trauma. J Urol 172:186–188
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Additional information
Weitere Literatur kann beim Verfasser angefordert werden.
Rights and permissions
About this article
Cite this article
Hauptmann, A., Diemer, T. & Weidner, W. Induratio penis plastica (IPP). Urologe 50, 609–620 (2011). https://doi.org/10.1007/s00120-011-2517-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-011-2517-7